CN Mobile Logo


Cancer Complications

ASCO 2016 Genitourinary Cancers Symposium

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium, held January 7–9 in San Francisco. We’ll bring you reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way genitourinary cancers are managed and treated.

Cancer Complications

A number of clinical and sociodemographic factors, including age and gender, were found to be independently associated with fatigue and depression among cancer patients who were treated with hematopoietic cell transplantation.

Some adult-onset cancer survivors have an increased risk of developing cardiovascular disease later in life compared to noncancer controls.

Adult survivors of childhood astroglial tumors with significant vision loss are more likely to suffer various psychological and socioeconomic impacts such as unemployment.

A study of female cancer survivors found that almost half experience CIPN symptoms years after completing their cancer treatment.

Administering pharmacological prophylaxis against venous thromboembolism (VTE) did not decrease the occurrence of VTE in patients treated with robotic partial nephrectomy, and it did not increase the rate of hemorrhagic events.

The US Food and Drug Administration granted approval to uridine triacetate (Vistogard) as a treatment for overdose of fluorouracil or capecitabine, which are administered for a number of malignancies.

Patients with metastatic or unresectable urothelial carcinoma who are treated with either carboplatin or cisplatin have high rates of vascular thromboembolic events.


Subscribe to Cancer Complications on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.